110 related articles for article (PubMed ID: 21961709)
1. Designing hypothesis of substituted benzoxazinones as HIV-1 reverse transcriptase inhibitors: QSAR approach.
Veerasamy R; Subramaniam DK; Chean OC; Ying NM
J Enzyme Inhib Med Chem; 2012 Oct; 27(5):693-707. PubMed ID: 21961709
[TBL] [Abstract][Full Text] [Related]
2. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
3. QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors.
Balaji S; Karthikeyan C; Moorthy NS; Trivedi P
Bioorg Med Chem Lett; 2004 Dec; 14(24):6089-94. PubMed ID: 15546736
[TBL] [Abstract][Full Text] [Related]
4. QSAR study of PETT derivatives as potent HIV-1 reverse transcriptase inhibitors.
Sabet R; Fassihi A; Moeinifard B
J Mol Graph Model; 2009 Sep; 28(2):146-55. PubMed ID: 19570701
[TBL] [Abstract][Full Text] [Related]
5. Linear and nonlinear quantitative structure-activity relationship modeling of the HIV-1 reverse transcriptase inhibiting activities of thiocarbamates.
Goodarzi M; Freitas MP; Vander Heyden Y
Anal Chim Acta; 2011 Oct; 705(1-2):166-73. PubMed ID: 21962359
[TBL] [Abstract][Full Text] [Related]
6. Predicting anti-HIV activity of 1,3,4-thiazolidinone derivatives: 3D-QSAR approach.
Ravichandran V; Prashantha Kumar BR; Sankar S; Agrawal RK
Eur J Med Chem; 2009 Mar; 44(3):1180-7. PubMed ID: 18687505
[TBL] [Abstract][Full Text] [Related]
7. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
[TBL] [Abstract][Full Text] [Related]
8. Quantitative structure-activity relationship studies on 2-amino-6-arylsulfonylbenzonitriles as human immunodeficiency viruses type 1 reverse transcriptase inhibitors using descriptors obtained from substituents and whole molecular structures.
Hemmateenejad B; Sabet R; Fassihi A
Chem Biol Drug Des; 2009 Oct; 74(4):405-15. PubMed ID: 19691465
[TBL] [Abstract][Full Text] [Related]
9. ANN QSAR workflow for predicting the inhibition of HIV-1 reverse transcriptase by pyridinone non-nucleoside derivatives.
Barzegar A; Zamani-Gharehchamani E; Kadkhodaie-Ilkhchi A
Future Med Chem; 2017 Jul; 9(11):1175-1191. PubMed ID: 28722475
[TBL] [Abstract][Full Text] [Related]
10. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors.
Ravichandran V; Shalini S; Sundram K; Sokkalingam AD
Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
[TBL] [Abstract][Full Text] [Related]
12. Monte Carlo sampling and multivariate adaptive regression splines as tools for QSAR modelling of HIV-1 reverse transcriptase inhibitors.
Alamdari RF; Mani-Varnosfaderani A; Asadollahi-Baboli M; Khalafi-Nezhad A
SAR QSAR Environ Res; 2012 Oct; 23(7-8):665-82. PubMed ID: 22746992
[TBL] [Abstract][Full Text] [Related]
13. Quantitative structure-activity relationship studies on 1-aryl-tetrahydroisoquinoline analogs as active anti-HIV agents.
Chen KX; Xie HY; Li ZG; Gao JR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5381-6. PubMed ID: 18835162
[TBL] [Abstract][Full Text] [Related]
14. QSAR for anti-HIV activity of HEPT derivatives.
Bazoui H; Zahouily M; Boulajaaj S; Sebti S; Zakarya D
SAR QSAR Environ Res; 2002 Oct; 13(6):567-77. PubMed ID: 12479372
[TBL] [Abstract][Full Text] [Related]
15. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.
Gussio R; Pattabiraman N; Zaharevitz DW; Kellogg GE; Topol IA; Rice WG; Schaeffer CA; Erickson JW; Burt SK
J Med Chem; 1996 Apr; 39(8):1645-50. PubMed ID: 8648604
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors.
de Brito MA; Rodrigues CR; Cirino JJ; de Alencastro RB; Castro HC; Albuquerque MG
J Chem Inf Model; 2008 Aug; 48(8):1706-15. PubMed ID: 18671385
[TBL] [Abstract][Full Text] [Related]
17. Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads.
Vadivelan S; Deeksha TN; Arun S; Machiraju PK; Gundla R; Sinha BN; Jagarlapudi SA
Eur J Med Chem; 2011 Mar; 46(3):851-9. PubMed ID: 21272964
[TBL] [Abstract][Full Text] [Related]
18. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
19. A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
Kireev DB; Chrétien JR; Grierson DS; Monneret C
J Med Chem; 1997 Dec; 40(26):4257-64. PubMed ID: 9435895
[TBL] [Abstract][Full Text] [Related]
20. A Structure-Activity Relationship Study of Imidazole-5-Carboxylic Acid Derivatives as Angiotensin II Receptor Antagonists Combining 2D and 3D QSAR Methods.
Sharma MC
Interdiscip Sci; 2016 Mar; 8(1):1-10. PubMed ID: 26202941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
